Repligen Corporation Insider Trading

RGEN

Last 12 months

Insiders sold $15.3M and bought nothing on the open market.

77% of the selling was scheduled in advance under 10b5-1 plans. Director Anthony Hunt sold $3.09M on Nov 13, 2025, 19% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2025.

Net open-market

−$15.3M

0 buys · 13 sales

Under a 10b5-1 plan

77%

of the value sold

Insiders who bought / sold

0 / 5

executives and directors

Last open-market buy

Aug 2025

Aug 8, 2025

Get an email when RGEN's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan 2 parts	5,535	$187.29 average	$1.04M	11%	Form 4
Sep 24	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan 2 parts	12,946	$190.00 average	$2.46M	21%	Form 4
Sep 21	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan	5,426	$180.00	977K	10%	Form 4
Sep 4	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan	3,035	$165.90	504K	5.9%	Form 4
Aug 20	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan	5,426	$180.00	977K	9.1%	Form 4
Jul 16	Jason K Garland CFO	Sold10b5-1 plan	530	$150.00	80K	2.7%	Form 4
Jun 25	Jason K Garland CFO	Sold10b5-1 plan	733	$145.00	106K	3.6%	Form 4
Apr 21	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan	3,832	$140.00	536K	6.6%	Form 4
Dec 17, 2025	Karen A Dawes Director	SoldNo plan	275	$161.00	44K	0.3%	Form 4
Nov 25, 2025	Olivier Loeillot Chief Executive Officer	Sold10b5-1 plan	7,041	$170.00	$1.2M	16%	Form 4
Nov 18, 2025	James Bylund Chief Operating Officer	SoldNo plan	2,191	$151.21	331K	9.2%	Form 4
Nov 13, 2025	Anthony Hunt Director	SoldNo plan 7 parts	20,000	$154.61 average	$3.09M	19%	Form 4
Nov 12, 2025	Anthony Hunt Director	Sold10b5-1 plan 5 parts	25,000	$156.88 average	$3.92M	20%	Form 4
Sep 10, 2025	Anthony Hunt Director	SoldNo plan 6 parts	29,111	$120.52 average	$3.51M	22%	Form 4
Aug 8, 2025	Martin D Madaus Director	Bought	1,800	$112.13	202K	32%	Form 4
May 15, 2025	Anthony Hunt Director	Sold10b5-1 plan 5 parts	26,447	$123.71 average	$3.27M	19%	Form 4
Mar 17, 2025	Anthony Hunt Director	Sold10b5-1 plan 6 parts	26,756	$152.51 average	$4.08M	16%	Form 4
Mar 17, 2025	Margaret Pax Director	Bought	250	$150.69	38K	32%	Form 4
Nov 21, 2024	Anthony Hunt Director	SoldNo plan	24,246	$139.67	$3.39M	15%	Form 4

Oct 510b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 5,535 at avg $187.29
$1.04M
11% of stake
Sep 2410b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 12,946 at avg $190.00
$2.46M
21% of stake
Sep 2110b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 5,426 at $180.00
977K
10% of stake
Sep 410b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 3,035 at $165.90
504K
5.9% of stake
Aug 2010b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 5,426 at $180.00
977K
9.1% of stake
Jul 1610b5-1 plan
Jason K Garland
CFO · sold 530 at $150.00
80K
2.7% of stake
Jun 2510b5-1 plan
Jason K Garland
CFO · sold 733 at $145.00
106K
3.6% of stake
Apr 2110b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 3,832 at $140.00
536K
6.6% of stake
Dec 17, 2025No plan
Karen A Dawes
Director · sold 275 at $161.00
44K
0.3% of stake
Nov 25, 202510b5-1 plan
Olivier Loeillot
Chief Executive Officer · sold 7,041 at $170.00
$1.2M
16% of stake
Nov 18, 2025No plan
James Bylund
Chief Operating Officer · sold 2,191 at $151.21
331K
9.2% of stake
Nov 13, 2025No plan
Anthony Hunt
Director · sold 20,000 at avg $154.61
$3.09M
19% of stake
Nov 12, 202510b5-1 plan
Anthony Hunt
Director · sold 25,000 at avg $156.88
$3.92M
20% of stake
Sep 10, 2025No plan
Anthony Hunt
Director · sold 29,111 at avg $120.52
$3.51M
22% of stake
Aug 8, 2025
Martin D Madaus
Director · bought 1,800 at $112.13
202K
32% of stake
May 15, 202510b5-1 plan
Anthony Hunt
Director · sold 26,447 at avg $123.71
$3.27M
19% of stake
Mar 17, 202510b5-1 plan
Anthony Hunt
Director · sold 26,756 at avg $152.51
$4.08M
16% of stake
Mar 17, 2025
Margaret Pax
Director · bought 250 at $150.69
38K
32% of stake
Nov 21, 2024No plan
Anthony Hunt
Director · sold 24,246 at $139.67
$3.39M
15% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RGEN, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with RGEN

CompareIntrinsic value

BCRXBioCryst Pharmaceuticals Inc.

$8.24-3.85%64

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

ADMAAdma Biologics Inc.

$10.48-5.67%82

KRYSKrystal Biotech Inc.

$310.84+1.90%44

TWSTTwist Bioscience Corporation

$142.58+1.63%40

IMCRImmunocore Holdings plc

$29.23-2.66%40

NVAXNovavax Inc.

$10.65+10.02%10

MGTXMeiraGTx Holdings plc

$9.42-1.05%74

Held by ETFs

RGEN is in 122 US ETFs. The largest of them, with RGEN's weight in each:

Spot a number that looks wrong? Check it in RGEN's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RGEN

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.